OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
ACCN57

Accent Microcell Ltd

PharmaceuticalsVerified

Accent Microcell Ltd maintains a strong capital structure with a debt-to-equity ratio of 0.01, indicating minimal leverage and a conservative financing approach. The company's liquidity position is characterized by a current ratio of 5.08, suggesting robust short-term liquidity and the ability to meet immediate obligations. However, the risk assessment notes a liquidity risk due to negative net cash after subtracting total debt, which could affect operational flexibility. In terms of profitability, the company demonstrates a return on equity of 33.95% and a return on assets of 28.95%, both significantly above the typical thresholds for the pharmaceutical industry, indicating strong operational efficiency and asset utilization. The gross profit margin of 31.04% (calculated from revenue and gross profit) and an operating margin of 28.99% (calculated from revenue and operating income) further underscore the company's profitability. The company's revenue is distributed across three segments: Dahej (SEZ Unit), Pirana, and Unit III. While the input data does not specify the exact revenue contribution of each segment, the global presence in over 75 countries suggests a diversified geographic exposure, reducing the risk of over-reliance on any single market. Accent Microcell Ltd's growth trajectory is supported by a strong operating cash flow of INR 493.46 million and a free cash flow of INR 314.07 million, indicating the company's ability to fund operations and reinvest in growth opportunities. The capital expenditure of INR -368.28 million suggests a focus on optimizing existing assets rather than significant new investments. The risk assessment highlights a medium liquidity risk and a low dilution risk. The company's low dilution potential is supported by the absence of significant dilution sources in the input data, and the risk assessment does not indicate any imminent pressure for equity issuance. The company's conservative capital structure and strong profitability metrics contribute to a favorable risk profile. Recent events and filings do not provide specific details in the input data, but the company's financial performance and operational metrics suggest a stable and growing business. The absence of significant negative events in the input data supports a positive outlook for the company's near-term performance.

30-day price · ACCN+78.25 (+21.6%)
Low$355.00High$481.00Close$440.70As of12 May, 00:00 UTC
Profile
CompanyAccent Microcell Ltd
TickerACCN.NS
SectorHealthcare
BusinessPharmaceuticals & Medical Research
Industry groupPharmaceuticals & Medical Research
IndustryPharmaceuticals
AI analysis

Business. Accent Microcell Ltd is a global manufacturer of microcrystalline cellulose, producing pharmaceutical excipients for applications in pharmaceuticals, nutraceuticals, food, cosmeceuticals, and other industrial sectors.

Classification. Accent Microcell Ltd is classified under the Pharmaceuticals industry within the Healthcare economic sector, with a confidence level of 0.92.

Accent Microcell Ltd maintains a strong capital structure with a debt-to-equity ratio of 0.01, indicating minimal leverage and a conservative financing approach. The company's liquidity position is characterized by a current ratio of 5.08, suggesting robust short-term liquidity and the ability to meet immediate obligations. However, the risk assessment notes a liquidity risk due to negative net cash after subtracting total debt, which could affect operational flexibility. In terms of profitability, the company demonstrates a return on equity of 33.95% and a return on assets of 28.95%, both significantly above the typical thresholds for the pharmaceutical industry, indicating strong operational efficiency and asset utilization. The gross profit margin of 31.04% (calculated from revenue and gross profit) and an operating margin of 28.99% (calculated from revenue and operating income) further underscore the company's profitability. The company's revenue is distributed across three segments: Dahej (SEZ Unit), Pirana, and Unit III. While the input data does not specify the exact revenue contribution of each segment, the global presence in over 75 countries suggests a diversified geographic exposure, reducing the risk of over-reliance on any single market. Accent Microcell Ltd's growth trajectory is supported by a strong operating cash flow of INR 493.46 million and a free cash flow of INR 314.07 million, indicating the company's ability to fund operations and reinvest in growth opportunities. The capital expenditure of INR -368.28 million suggests a focus on optimizing existing assets rather than significant new investments. The risk assessment highlights a medium liquidity risk and a low dilution risk. The company's low dilution potential is supported by the absence of significant dilution sources in the input data, and the risk assessment does not indicate any imminent pressure for equity issuance. The company's conservative capital structure and strong profitability metrics contribute to a favorable risk profile. Recent events and filings do not provide specific details in the input data, but the company's financial performance and operational metrics suggest a stable and growing business. The absence of significant negative events in the input data supports a positive outlook for the company's near-term performance.
Key takeaways
  • Accent Microcell Ltd has a strong profitability profile with a return on equity of 33.95% and a return on assets of 28.95%.
  • The company maintains a conservative capital structure with a debt-to-equity ratio of 0.01 and a current ratio of 5.08.
  • Accent Microcell Ltd's global presence in over 75 countries suggests a diversified geographic exposure.
  • The company's operating cash flow of INR 493.46 million and free cash flow of INR 314.07 million indicate strong liquidity and financial flexibility.
  • The risk assessment indicates a medium liquidity risk and a low dilution risk, supporting a favorable risk profile.
  • --
  • # RATIONALES
  • ```json
Financial snapshot
PeriodHA-latest
CurrencyINR
Revenue$2.65B
Gross profit$821.4M
Operating income$766.5M
Net income$661.3M
R&D
SG&A
D&A
SBC
Operating cash flow$493.5M
CapEx-$368.3M
Free cash flow$314.1M
Total assets$2.28B
Total liabilities$335.8M
Total equity$1.95B
Cash & equivalents
Long-term debt$15.1M
Annual history (last 5)
PeriodRevenueOp IncomeNet IncomeFCF
FY0
FY-1
FY-2
FY-3
FY-4
PeriodGross %Op %Net %FCF %
FY0
FY-1
FY-2
FY-3
FY-4
PeriodAssetsEquityCashDebt
FY0
FY-1
FY-2
FY-3
FY-4
PeriodOCFCapExFCFSBC
FY0
FY-1
FY-2
FY-3
FY-4
Quarterly history (last 4)
PeriodRevenueOp IncomeNet IncomeFCF
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodGross %Op %Net %FCF %
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodAssetsEquityCashDebt
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodOCFCapExFCFSBC
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
Valuation
Market price
Market cap
Enterprise value
P/E
Reported non-GAAP P/E
EV/Revenue
EV/Op income
EV/OCF
P/B
P/Tangible book
Tangible book$1.95B
Net cash-$15.1M
Current ratio5.1
Debt/Equity0.0
ROA28.9%
ROE34.0%
Cash conversion75.0%
CapEx/Revenue-13.9%
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskMedium
  • Net cash is negative after subtracting total debt.
Industry benchmarks
Activity: Pharmaceuticals · cohort 25 companies
MetricACCNActivity
Op margin29.0%18.2% medp25 18.2% · p75 24.6%top quartile
Net margin25.0%14.7% medp25 11.7% · p75 28.1%above median
Gross margin31.0%19.7% medp25 19.7% · p75 39.8%above median
R&D / revenue24.3% medp25 6.6% · p75 24.3%
CapEx / revenue-13.9%4.9% medp25 4.2% · p75 6.3%bottom quartile
Debt / equity1.0%71.3% medp25 19.0% · p75 91.7%bottom quartile
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod FQ-7 · history via verified-market-data
no public URL
2026-05-10 11:44 UTC#65d33a1d
Source: analysis-pipeline (hybrid)Generated: 2026-05-10 11:46 UTCJob: d75ddc5f